-
GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership
•
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn from the US industry trade group Biotechnology Innovation Organization (BIO). This decision follows a similar trend set by Pfizer (NSE: PFIZER), UCB (EBR: UCB), WuXi AppTec (HKG: 2359, SHA: 603259), Takeda (TYO: 4502), and other…
-
Pfizer Partners with TRIANA Biomedicines to Develop Molecular Glue Degraders for Oncology and Other Diseases
•
Pfizer (NSE: PFIZER), a leading US pharmaceutical company, has entered into a strategic partnership and licensing agreement with Massachusetts-based biotech firm TRIANA Biomedicines. The collaboration aims to develop innovative molecular glue degraders targeting a variety of diseases, with a focus on oncology, according to a press release from TRIANA. Under…
-
China’s CDE Announces “Care Plan” to Include Pfizer’s Marstaximab for Rare Disease Drug Development
•
The National Health Commission (NHC) of China, through its Center for Drug Evaluation (CDE), has announced that Pfizer (NSE: PFIZER, NYSE: PFE, ETR: PFE)’s Marstaximab (PF-06741086) has been included in the “Care Plan” for patient-centered rare disease drug development. The publicity period for this decision ends on October 12, 2024.…
-
Pfizer Partners with Shanghai Pharmaceutical for Long-Term Vaccine Collaboration in China
•
Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S., has entered into a partnership with China’s Shanghai Pharmaceutical Holding Co., Ltd (SHA: 601607; SPH) to establish a long-term collaboration in the vaccine sector. The collaboration will focus on product promotion, introduction of innovative products,…
-
Pfizer’s Once-Daily Danuglipron Selected for Full Clinical Development for Type 2 Diabetes and Obesity
•
Pfizer Inc. (NSE: PFIZER), a leading pharmaceutical company in the U.S., has announced that a once-daily oral formulation of danuglipron, its investigational GLP-1 agonist for the treatment of type 2 diabetes and obesity, has been selected for full clinical development. This decision is based on positive findings from an ongoing…
-
Pfizer to Establish Smart Medical Innovation Center in Hangzhou’s Qiantang District
•
US pharmaceutical giant Pfizer (NSE: PFIZER) has announced a plan to establish a smart medical innovation center in the Qiantang district of Hangzhou city in China. This initiative aims to bolster the Chinese medical industry’s digital innovation capabilities and contribute to the advancement of healthcare solutions in the region. Empowering…
